mRNA-based HIV-1 vaccines
S Ahmed, A Herschhorn - Clinical microbiology reviews, 2024 - journals.asm.org
The success of the Severe Acute Respiratory Syndrome Coronavirus 2 mRNA vaccines to
lessen/prevent severe COVID-19 opened new opportunities to develop RNA vaccines to …
lessen/prevent severe COVID-19 opened new opportunities to develop RNA vaccines to …
Conformational flexibility of HIV-1 envelope glycoproteins modulates transmitted/founder sensitivity to broadly neutralizing antibodies
D Parthasarathy, KR Pothula, S Ratnapriya… - Nature …, 2024 - nature.com
Abstract HIV-1 envelope glycoproteins (Envs) of most primary HIV-1 strains exist in closed
conformation and infrequently sample open states, limiting access to internal epitopes. Thus …
conformation and infrequently sample open states, limiting access to internal epitopes. Thus …
HIResist: a database of HIV-1 resistance to broadly neutralizing antibodies
Motivation Changing the course of the human immunodeficiency virus type I (HIV-1)
pandemic is a high public health priority with approximately 39 million people currently living …
pandemic is a high public health priority with approximately 39 million people currently living …
Characterization of bi-segmented and tri-segmented recombinant Pichinde virus particles
H Murphy, Q Huang, J Jensen, N Weber… - Journal of …, 2024 - journals.asm.org
Mammarenaviruses include several highly virulent pathogens (eg, Lassa virus) capable of
causing severe hemorrhagic fever diseases for which there are no approved vaccines and …
causing severe hemorrhagic fever diseases for which there are no approved vaccines and …
Alternative substitutions of N332 in HIV-1AD8 gp120 differentially affect envelope glycoprotein function and viral sensitivity to broadly neutralizing antibodies targeting …
The envelope glycoprotein (Env) trimer on the surface of human immunodeficiency virus
type I (HIV-1) mediates viral entry into host CD4+ T cells and is the sole target of neutralizing …
type I (HIV-1) mediates viral entry into host CD4+ T cells and is the sole target of neutralizing …
[HTML][HTML] Development of a Two-Component Nanoparticle Vaccine Displaying an HIV-1 Envelope Glycoprotein that Elicits Tier 2 Neutralising Antibodies
K Malebo, J Woodward, P Ximba, Q Mkhize, S Cingo… - Vaccines, 2024 - mdpi.com
Despite treatment and other interventions, an effective prophylactic HIV vaccine is still an
essential goal in the control of HIV. Inducing robust and long-lasting antibody responses is …
essential goal in the control of HIV. Inducing robust and long-lasting antibody responses is …
[PDF][PDF] Bridging One Health: Computational design of a multi-epitope messenger RNA vaccine for cross-species immunization against Nipah virus
Abstract Background and Aim: Nipah virus (NiV) poses a threat to human and animal health,
particularly swine, which serve as primary vectors for human transmission. Despite its …
particularly swine, which serve as primary vectors for human transmission. Despite its …
Insights from HIV-1 vaccine and passive immunization efficacy trials
S Ahmed, A Herschhorn, AL Epstein, SD Rabkin - Safety, 2024 - cell.com
An effective HIV-1 vaccine is still not available, and most vaccine efficacy trials conducted
over the years resulted in no significant overall protection. Here we highlight several insights …
over the years resulted in no significant overall protection. Here we highlight several insights …